| Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial J Chataway, F De Angelis, P Connick, RA Parker, D Plantone, A Doshi, ... The Lancet Neurology 19 (3), 214-225, 2020 | 108 | 2020 |
| Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing … P Connick, F De Angelis, RA Parker, D Plantone, A Doshi, N John, ... BMJ open 8 (8), e021944, 2018 | 54 | 2018 |
| Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study HP Hartung, T Derfuss, BAC Cree, MP Sormani, K Selmaj, J Stutters, ... Multiple Sclerosis Journal 28 (3), 429-440, 2022 | 53 | 2022 |
| Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study JWL Brown, NG Cunniffe, F Prados, B Kanber, JL Jones, E Needham, ... The Lancet Neurology 20 (9), 709-720, 2021 | 53 | 2021 |
| A brain-derived metric for preferred kinetic stimuli S Zeki, J Stutters Open biology 2 (2), 120001, 2012 | 41 | 2012 |
| Functional specialization and generalization for grouping of stimuli based on colour and motion S Zeki, J Stutters Neuroimage 73, 156-166, 2013 | 39 | 2013 |
| Association of slowly expanding lesions on MRI with disability in people with secondary progressive multiple sclerosis A Calvi, FP Carrasco, C Tur, DT Chard, J Stutters, F De Angelis, N John, ... Neurology 98 (17), e1783-e1793, 2022 | 34 | 2022 |
| Predicting disability progression and cognitive worsening in multiple sclerosis using patterns of grey matter volumes E Colato, J Stutters, C Tur, S Narayanan, DL Arnold, ... Journal of Neurology, Neurosurgery & Psychiatry 92 (9), 995-1006, 2021 | 32 | 2021 |
| Slowly expanding lesions relate to persisting black-holes and clinical outcomes in relapse-onset multiple sclerosis A Calvi, C Tur, D Chard, J Stutters, O Ciccarelli, R Cortese, M Battaglini, ... NeuroImage: Clinical 35, 103048, 2022 | 19 | 2022 |
| Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT F De Angelis, P Connick, RA Parker, D Plantone, A Doshi, N John, ... Efficacy and Mechanism Evaluation 7 (3), 1-72, 2020 | 16 | 2020 |
| NAA is a marker of disability in secondary-progressive MS: A proton MR spectroscopic imaging study BS Solanky, NA John, F DeAngelis, J Stutters, F Prados, T Schneider, ... American Journal of Neuroradiology 41 (12), 2209-2218, 2020 | 15 | 2020 |
| Brain and cervical spinal cord atrophy in primary progressive multiple sclerosis: results from a placebo-controlled phase III trial (INFORMS) Ö Yaldizli, D MacManus, J Stutters, DA Häring, F Lublin, MS Freedman, ... MULTIPLE SCLEROSIS JOURNAL 21, 30-31, 2015 | 13 | 2015 |
| Colournamer, a synthetic observer for colour communication D Mylonas, J Stutters, V Doval, L MacDonald NewcastleGateshead Convention Bureau, 2013 | 9 | 2013 |
| Remyelination varies between and within lesions in multiple sclerosis following bexarotene JWL Brown, F Prados, DR Altmann, B Kanber, J Stutters, NG Cunniffe, ... Annals of clinical and translational neurology 9 (10), 1626-1642, 2022 | 6 | 2022 |
| MS-SMART Trial: a multi-arm phase 2b randomised, double blind, parallel group, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in … J Chataway, F De Angelis, P Connick, R Parker, D Plantone, A Doshi, ... MULTIPLE SCLEROSIS JOURNAL 24, 986-987, 2018 | 5 | 2018 |
| Networks of microstructural damage predict disability in multiple sclerosis E Colato, F Prados, J Stutters, A Bianchi, S Narayanan, DL Arnold, ... Journal of Neurology, Neurosurgery & Psychiatry 94 (12), 992-1003, 2023 | 3 | 2023 |
| Phase 2 clinical trial evidence that a retinoid-X receptor agonist promotes remyelination in people with relapsing-remitting multiple sclerosis J Brown, N Cunniffe, F Prados, B Kanber, J Jones, E Needham, ... MULTIPLE SCLEROSIS JOURNAL 26 (3_ SUPPL), 43-44, 2020 | 3 | 2020 |
| LB01. 02-Phase 2 clinical trial evidence that a retinoid-X receptor agonist promotes remyelination in people with relapsing-remitting multiple sclerosis J Brown, N Cunniffe, F Prados MSVirtual2020 (formerly 8th Joint Meeting ACTRIMS-ECTRIMS Annual Congress), 2020 | 3 | 2020 |
| Treatment reduces the incidence of newly appearing multiple sclerosis lesions evolving into chronic active, slowly expanding lesions: A retrospective analysis A Calvi, Z Mendelsohn, W Hamed, D Chard, C Tur, J Stutters, ... European journal of neurology 31 (1), e16092, 2024 | 2 | 2024 |
| Longitudinal metabolite changes in progressive multiple sclerosis: a study of 3 potential neuroprotective treatments NA John, BS Solanky, F De Angelis, RA Parker, CJ Weir, J Stutters, ... Journal of Magnetic Resonance Imaging, 2023 | 2 | 2023 |
Frederik BarkhofVU University Medical CenterVerified email at vumc.nl
